Compare Ascendis Pharma A/S (ASND) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Palantir Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Palantir Technologies Inc trades at $127.45 (market cap $303.96B). The key difference: Palantir Technologies Inc is far larger — about 17.1× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PLTR | |
|---|---|---|
Market Cap | $17.74B | $303.96B |
Sector | Health | Technology |
52-Week High | $277.18 | $207.18 |
52-Week Low | $163.32 | $107.27 |
Enterprise Value | $18.11B | $296.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PLTR trades at $126.79, down 1.74% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong fundamentals, with Q1 2026 EPS of $0.33 beating expectations, revenue growth accelerating to 85% YoY, and a net income margin of 43.67%. Recent news highlights CEO commentary on AI competition and robust U.S. revenue expansion of 104%.
The outlook remains positive given earnings beats and growth trajectory, but high valuation multiples (P/E 142.46) pose a risk if growth slows. Analyst consensus price target is $185.67, suggesting upside, though bearish technicals and sector volatility warrant caution for near-term entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
